Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Studies examine risk factors for hospital readmission

Studies examine risk factors for hospital readmission

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

NBM 200 system accurately measures hemoglobin level

NBM 200 system accurately measures hemoglobin level

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos announces favorable survival data from FOLOTYN Phase 2b study

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

Dr. Bessler joins Children's Hospital of Philadelphia

Dr. Bessler joins Children's Hospital of Philadelphia

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

DaVita announces $1.45 billion Senior Notes offering

DaVita announces $1.45 billion Senior Notes offering

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.